AI Article Synopsis

  • Hidradenitis suppurativa (HS) is a skin condition linked to systemic inflammation, obesity, and metabolic syndrome, with few effective treatment options available.
  • Incretins, antidiabetic agents, have shown success in treating psoriasis, which is also related to metabolic syndrome.
  • A case study reveals that liraglutide, a glucagon-like peptide-1 agonist, helped a patient with HS by promoting weight loss and improving disease management, marking the first documented use of this drug for HS treatment.

Article Abstract

Hidradenitis suppurativa (HS) is a cutaneous disease associated with systemic inflammation, obesity and metabolic syndrome. Effective treatment options are limited. The antidiabetic agents, incretins, have been used successfully to treat psoriasis - a disease also associated with metabolic syndrome. We report the use of liraglutide, a glucagon-like peptide-1 agonist, in a patient with HS, leading to subsequent weight loss and improvement in disease control. To our knowledge, this is the first report of liraglutide used in the treatment of HS.

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.15233DOI Listing

Publication Analysis

Top Keywords

hidradenitis suppurativa
8
glucagon-like peptide-1
8
peptide-1 agonist
8
disease associated
8
metabolic syndrome
8
report liraglutide
8
treatment hidradenitis
4
suppurativa glucagon-like
4
agonist liraglutide
4
liraglutide hidradenitis
4

Similar Publications

Importance: Surgery is frequently required for hidradenitis suppurativa (HS) treatment, but the impact of common comorbidities such as obesity, diabetes, and smoking on outcomes has been sparsely studied.

Observations: A total of 12 studies met final inclusion criteria for investigating complication rates associated with at least 1 comorbidity. Complication rates were associated with obesity in 3 of 10 studies.

View Article and Find Full Text PDF

Importance: Variation in nicastrin (NCSTN) is associated with a monogenic subtype of hidradenitis suppurativa. Dysregulation of humoral immunity has been suggested as a potential mechanistic link between NCSTN variation and hidradenitis suppurativa. There is a paucity of biomarkers that can predict disease-associated variation.

View Article and Find Full Text PDF

Interleukin-17: A pleiotropic cytokine implicated in inflammatory, infectious, and malignant disorders.

Cytokine Growth Factor Rev

January 2025

MCW Cancer Center and Genomic Sciences and Precision Medicine Center, Medical College of Wisconsin, Milwaukee, WI, USA; WIN Consortium, Paris, France; University of Nebraska, Lincoln, NE, USA. Electronic address:

IL-17A, referred to as IL-17, is the founding member of a family of pro-inflammatory cytokines, including IL-17B, IL-17C, IL-17D, IL-17E (or IL-25), and IL-17F, which act via receptors IL-17RA to IL-17RE, and elicit potent cellular responses that impact diverse diseases. IL-17's interactions with various cytokines include forming a heterodimer with IL-17F and being stimulated by IL-23's activation of Th17 cells, which can lead to inflammation and autoimmunity. IL-17 is implicated in infectious diseases and inflammatory disorders such as rheumatoid arthritis and psoriasis, promoting neutrophil recruitment and anti-bacterial immunity, but potentially exacerbating fungal and viral infections, revealing its dual role as protective and pathologic.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!